Three might be company for antiplatelet therapy after stenting

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1520, 2006-01, pp. : 14-14

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Duration of Dual Antiplatelet Therapy After Coronary Stenting

Current Pharmaceutical Design, Vol. 22, Iss. 29, 2016-09 ,pp. : 4583-4595

Bentham Science Publishers

Access to resources Recommend Favorite

Advances in antiplatelet therapy

By Jneid Hani Bhatt Deepak L

Expert Opinion on Emerging Drugs, Vol. 8, Iss. 2, 2003-11 ,pp. : 349-363

Informa Healthcare

Access to resources Recommend Favorite

New Perspectives in Antiplatelet Therapy

Current Medicinal Chemistry, Vol. 19, Iss. 3, 2012-01 ,pp. : 406-427

Bentham Science Publishers

Access to resources Recommend Favorite

Prasugrel versus Clopidogrel Antiplatelet Therapy after Acute Coronary Syndrome: Matching Treatments with Patients

By Tcheng James E.

American Journal of Cardiovascular Drugs, Vol. 12, Iss. 2, 2012-04 ,pp. : 83-91

Adis International

Access to resources Recommend Favorite

Dual antiplatelet therapy (DAT) was associated with an increased haemorrhage risk after drug-eluting stent (DES) placement

Inpharma, Vol. 1, Iss. 1632, 2008-01 ,pp. : 25-25

Adis International

Access to resources Recommend Favorite